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ABSTRACT
Objectives: To compare the efficacy and safety of artemisinin combination therapies for the
treatment of uncomplicated falciparum malaria in Uganda.
Design: Randomized single-blind controlled trial.
Setting: Tororo, Uganda, an area of high-level malaria transmission.
Participants: Children aged one to ten years with confirmed uncomplicated P. falciparum
malaria.
Interventions: Amodiaquineþ artesunate or artemether–lumefantrine.
Outcome Measures: Risks of recurrent symptomatic malaria and recurrent parasitemia at 28
days, unadjusted and adjusted by genotyping to distinguish recrudescences and new infections.
Results: Of 408 participants enrolled, 403 with unadjusted efficacy outcomes were included in
the per-protocol analysis. Both treatment regimens were highly efficacious; no recrudescences
occurred in patients treated with amodiaquine þ artesunate, and only two occurred in those
treated with artemether–lumefantrine. However, recurrent malaria due to new infections was
common. The unadjusted risk of recurrent symptomatic malaria was significantly lower for
participants treated with artemether–lumefantrine than for those treated with amodiaquineþ
artesunate (27% versus 42%, risk difference 15%, 95% CI 5.9%–24.2%). Similar results were seen
for the risk of recurrent parasitemia (51% artemether–lumefantrine versus 66% amodiaquineþ
artesunate, risk difference 16%, 95% CI 6.2%–25.2%). Amodiaquine þ artesunate and
artemether–lumefantrine were both well-tolerated. Serious adverse events were uncommon
with both regimens.
Conclusions: Amodiaquine þ artesunate and artemether–lumefantrine were both highly
efficacious for treatment of uncomplicated malaria. However, in this holoendemic area, despite
the excellent performance of both regimens in terms of efficacy, many patients experienced
recurrent parasitemia due to new infections. Artemether–lumefantrine was superior to
amodiaquine þ artesunate for prevention of new infections. To maximize the benefit of
artemisinin combination therapy in Africa, treatment should be integrated with strategies to
prevent malaria transmission. The impact of frequent repeated therapy on the efficacy, safety,
and cost-effectiveness of new artemisinin regimens should be further investigated.
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INTRODUCTION
In Africa, widespread resistance of Plasmodium falciparum to
chloroquine and sulfadoxine–pyrimethamine has required
urgent introduction of alternative antimalarial therapies,
including artemisinin-based combination therapies (ACTs)
[1]. However, identifying appropriate regimens has been a
challenging task [2]. In Southeast Asia, ACTs have been highly
efﬁcacious and associated with reductions in morbidity,
gametocyte carriage, and malaria transmission [3,4]. How-
ever, there is relatively little experience with these drugs in
Africa, where malaria transmission intensity is substantially
greater and the pattern of antimalarial drug use is quite
different [5,6].
In Uganda, chloroquine þ sulfadoxine–pyrimethamine
replaced chloroquine as the ﬁrst-line recommended therapy
for uncomplicated malaria in 2002 [7]. Drug efﬁcacy studies
conducted at eight sites around the country subsequently
demonstrated quite poor efﬁcacy of chloroquine þ sulfadox-
ine–pyrimethamine [8–10]. As a result, artemether–lumefan-
trine was adopted as the new ﬁrst-line antimalarial treatment
in 2004, with amodiaquine þ artesunate as a substitute, if
artemether–lumefantrine was not readily available. However,
this policy was adopted when little comparative efﬁcacy and
safety data on artemether–lumefantrine was available from
Africa [11]. With shortages in drug supplies, limitations of
available resources, and logistical issues, to date the new
Ugandan drug policy has not been implemented. To inform
antimalarial policy in Uganda, and to further investigate
ACTs in Africa, we conducted a single-blind randomized
clinical trial to compare the efﬁcacy and safety of arte-
mether–lumefantrine and amodiaquine þ artesunate for the
treatment of uncomplicated falciparum malaria in Tororo,
an area of very high transmission intensity.
METHODS
Study Site
The study was conducted at Nagongera Health Centre,
Tororo District, Uganda. At this rural site, malaria is
holoendemic, occurring perennially with peaks following
the two rainy seasons, from March to May and from August
to September (Ugandan Ministry of Health, unpublished data,
1994). The entomological inoculation rate (number of
infective bites per person per year), a measure of transmission
intensity, was determined to be 591 in Nagongera, Tororo
District (A. Talisuna, Uganda Ministry of Health, personal
communication). The study protocol was approved by the
Uganda National Council of Science and Technology and the
institutional review boards of the University of California San
Francisco and the University of California Berkeley.
Participants
Patients presenting to the health centre with symptoms
suggestive of malaria and a positive screening thick blood
smear were consecutively referred to study physicians for
further assessment. Patients were enrolled if they fulﬁlled the
following selection criteria: 1) age one to ten years; 2) history
of fever in the previous 24 hours or axillary temperature
.37.5 8C; 3) no history of serious side effects to study
medications; 4) no evidence of a concomitant febrile illness;
5) provision of informed consent by a parent or guardian; 6)
no danger signs or evidence of severe malaria; and 7) P.
falciparum mono-infection with parasite density 2,000–
200,000/ll of blood. Because laboratory results were generally
not available until the following day, a patient could be
excluded after randomization. Patients were also excluded
after randomization if they repeatedly vomited their ﬁrst
dose of study medications.
Procedures
At enrollment, we asked children and their parents or
guardians about prior antimalarial therapy, use of other
medications, and presence of common symptoms. Axillary
temperature and weight were measured and a physical
examination was performed. A brief neurological assessment,
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Editorial Commentary
Background: Malaria parasites have become resistant in much of Africa
to many commonly used treatments, such as chloroquine and
sulfadoxine–pyrimethamine. Newer drugs, such as artemisinin-based
combination therapies (ACTs), have been used extensively in Southeast
Asia. Artemether–lumefantrine (an ACT) has now been adopted as first-
line malaria treatment in Uganda, with the combination of amodiaquine
and artesunate as a backup treatment. There are two ways that
successful treatment is measured; first by whether the treatment works
in curing the infection; and second by whether it prevents the disease
recurring—either the same infection (known as recrudescence), or a new
infection. The researchers wanted to look at how artemether–lumefan-
trine compared with amodiaquine and artesunate for treating sympto-
matic malaria, and also at whether there were any differences in
recurrence, either of clinical malaria, or of parasite infection without
symptoms, for 28 days after treatment.
What this trial shows: This randomized trial in young children with
confirmed malaria in Uganda showed that both treatments resulted in a
similar initial response to therapy, as measured by the risk of early
treatment failure (within three days). The researchers found that
artemether–lumefantrine was more effective at reducing the risk and
delayed the time to recurrence of malaria, compared with amodiaquine
and artesunate. Additionally, treatment with artemether–lumefantrine
resulted in a reduced rate of parasite infection without malaria
symptoms, as compared with amodiaquine and artesunate. Nearly all
cases of recurrent malaria after either treatment combination arose from
new infections, rather than from recrudescences.
Strengths and limitations: The trial was correctly designed to test the
questions of interest, and enough patients were recruited to properly
examine the relative effects of the two treatment combinations.
However, patients were only followed up for 28 days after treatment. A
longer follow-up period might have revealed a higher rate of recurrence
of malaria after treatment. In the trial, artemether–lumefantrine was not
administered with food, and it’s known that lumefantrine is absorbed
better when it is taken with a small amount of fat. It’s possible that the
effect of artemether–lumefantrine seen in the trial could have been an
underestimate of what might be achieved in ideal conditions.
Contribution to the evidence: This trial adds information on the
efficacy of artemether–lumefantrine as compared with amodiaquine and
artesunate in East Africa for treatment of uncomplicated (i.e., non-severe)
symptomatic malaria. The results are consistent with those of other trials
on the efficacy of ACTs that have been performed in the region. The
study also adds data on the risk of recurrent infections in an area where
malaria occurs very frequently. Even following treatment with either ACT,
the risk of recurrence was very high.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
consisting of simple clinical tests for hearing and ﬁne ﬁnger
dexterity (ability to pick up a small object) was undertaken.
We also obtained blood by ﬁngerprick for thick and thin
blood smears, hemoglobin assessment, and to store on ﬁlter
paper for molecular analysis.
Patients were asked to return for follow-up on days 1, 2, 3, 7,
14, 21, and 28, and any other day that they felt ill. Follow-up
evaluation consisted of a standardised history and physical
examination, including neurological assessment on days 7, 14,
and 28. We obtained blood by ﬁngerprick for thick blood
smears and storage on ﬁlter paper on all follow-up days
(except day 1). Hemoglobin measurement was repeated on day
28, or the day of recurrent symptomatic malaria. If patients
did not return for follow-up, we visited them at home.
Blood smears were stained with 2% Giemsa for 30 min.
Parasite densities were determined from thick blood smears
by counting the number of asexual parasites per 200 white
blood cells (or per 500, if the count was less than 10 parasites/
200 white blood cells), assuming a white blood cell count of
8,000/ll. A smear was considered negative if no parasites were
seen after review of 100 high-powered ﬁelds. We also assessed
gametocytemia from thick blood smears. Thin blood smears
were reviewed for non-falciparum infections. A second
microscopist, who was unaware of the results of the ﬁrst
reading, re-read all slides. A third microscopist unaware of
the ﬁrst two readings resolved discrepant slides. Hemoglobin
measurements were made using a portable spectrophotom-
eter (HemoCue, Anglholm, Sweden).
Interventions
On day 0, patients were randomly assigned to receive
amodiaquine þ artesunate or artemether–lumefantrine. A
nurse administered study medications according to weight-
based guidelines for administration of fractions of tablets
(amodiaquine and artesunate) and the manufacturer’s recom-
mendations (artemether–lumefantrine). We administered all
drugs orally as follows: amodiaquine (Camoquin, Parke-Davis,
Pﬁzer, New York, New York, United States of America), 200mg
tablets, 25mg/kg per treatment) 10mg/kg on days 0 and 1, and 5
mg/kg on day 2; and artesunate (Arsumax, Sanoﬁ-Aventis, Paris
France), 50 mg tablets, 12 mg/kg per treatment, 4 mg/kg once
daily for three days; artemether–lumefantrine (Coartem,
Novartis, Basel, Switzerland), 20 mg artemether/120 mg
lumefantrine tablets, 3-d six-dose regimen administered
according to weight, as one [10–14 kg], two [15–24 kg], three
[25–34 kg], or four [35 kg] tablets given twice daily for three
days. Participants in the amodiaquineþ artesunate group also
receivedplacebo tablets administered in the evening over three
days, dosed similarly to weight-based guidelines for arte-
mether–lumefantrine. Study medications were administered
with water. Although participants were encouraged to resume
normal food intake, no foodwasprovidedwith themedications.
All treatment was directly observed. Participants were
given the option either to wait at the clinic for the evening
dose (lunch was provided) or to leave the clinic and return in
the evening (transport was provided). After each dose,
children were observed for 30 min and the dose was
readministered if vomiting occurred. Children who repeat-
edly vomited their ﬁrst dose of study medication were
excluded from the study and referred for further manage-
ment. We provided all patients with a 3-day supply of
paracetamol for treatment of febrile symptoms. Those with a
concentration of hemoglobin of less than 10.0 g/dL were
treated according to Integrated Management of Childhood
Illness guidelines with ferrous sulfate for 14 days and given
antihelminthic treatment if appropriate.
Objectives
The objectives of the study were to compare the efﬁcacy and
safety of amodiaquineþ artesunate and artemether–lumefan-
trine for the treatment of uncomplicated falciparum malaria
in Uganda.
Outcomes—Efficacy
The primary efﬁcacy outcomes were the 28-d risks of
recurrent symptomatic malaria (early treatment failure and
late clinical failure) and recurrent parasitemia (early treat-
ment failure, late clinical failure, late parasitological failure),
unadjusted and adjusted by genotyping. Secondary efﬁcacy
outcomes included risk of fever and parasitemia during the
ﬁrst three days of follow-up, change in mean hemoglobin
from day 0 to day 28, or day of repeat therapy, and risk of
gametocytemia during follow-up in participants lacking
gametocytes at enrollment.
Treatment outcomes were classiﬁed according to 2003
WHO guidelines as early treatment failure (ETF; danger signs
or complicated malaria or failure to adequately respond to
therapy days 0–3), late clinical failure (LCF; danger signs or
complicated malaria or fever and parasitemia on days 4–28
without previously meeting criteria for ETF), late para-
sitological failure (LPF; asymptomatic parasitemia day 28
without previously meeting criteria for ETF or LCF), and
adequate clinical and parasitological response (ACPR; ab-
sence of parasitemia on day 28 without previously meeting
criteria for ETF, LCF, or LPF) [12]. Patients classiﬁed as
treatment failures were treated with quinine (10 mg/kg three
times daily for seven days). Patients were excluded after
enrollment if any of the following occurred: 1) use of
antimalarial drugs outside of the study protocol; 2) para-
sitemia in the presence of a concomitant febrile illness; 3)
withdrawal of consent; 4) loss to follow-up; 5) protocol
violation; and 6) death due to a non-malaria illness.
Molecular genotyping techniques were used to distinguish
recrudescent from new infections for all patients failing
therapy after day 3. Brieﬂy, ﬁlter paper blood samples
collected on the day of enrollment and on the day of failure
(LCF or LPF) were analyzed for polymorphisms in merozoite
surface protein-1 (MSP-1) and 2 (MSP-2) using nested-PCR
as previously described [13]. First, MSP-2 genotyping patterns
on the day of failure were compared with those at treatment
initiation using GelCompar II software for all paired samples
(Applied Maths, Sint-Martens-Latem, Belgium). If all of the
MSP-2 alleles present on the day of failure were present at the
time of treatment initiation, genotyping was repeated using
MSP-1. An outcome was deﬁned as recrudescence if all MSP-1
and MSP-2 alleles present at the time of failure were present
at the time of treatment initiation, and deﬁned as a new
infection otherwise.
Outcomes—Safety
Secondary safety outcomes included risk of serious adverse
events, and risk of events of moderate or greater severity. At
each follow-up visit, patients were assessed for any new or
worsening event. An adverse event was deﬁned as any
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untoward medical occurrence, irrespective of its suspected
relationship to the study medications (Guidance for Industry
Good Clinical Practice: Consolidated Guidance [ICH E6],
April 1996). All events were graded by severity (none, mild,
moderate, severe, life-threatening) and relationship to study
treatment (none, unlikely, possible, probable, or deﬁnite)
using guidelines from the World Health Organization
(Toxicity Grading Scale for Determining the Severity of
Adverse Events) and the National Institutes of Health,
Division of Microbiology and Infectious Diseases (Pediatric
Toxicity Tables, May 2001). A serious adverse event was
deﬁned as any adverse experience that resulted in death, life-
threatening experience, inpatient hospitalization, persistent
or signiﬁcant disability or incapacity, or speciﬁc medical or
surgical intervention to prevent serious outcome.
Sample Size
We calculated sample size to test the hypothesis that treatment
with artemether–lumefantrine would decrease the risk of
recurrent symptomatic malaria by 15% at 28 days compared
with amodiaquineþartesunate. The risk over 28 days of repeat
therapy for symptomatic malaria (unadjusted by genotyping)
with amodiaquineþartesunate was estimated as 50% based on
previous data [10]. Using this estimate, we calculated that 180
patients would need to be enrolled in each treatment arm (200
to allow for 10% loss to follow-up) to detect a 15% risk
difference between the treatment groups with a two-sided type
I error of 0.05 and 80%power. The sample size calculations for
this study were performed online using the followingWeb site:
http://statpages.org/proppowr.html.
Randomization Procedures—Sequence Generation,
Allocation Concealment, Implementation
An off-site investigator prepared computer-generated age-
stratiﬁed randomization codes for two age groups (12–59 mo
and 5–10 y) which were provided to a study nurse responsible
for treatment allocation. The randomization list was secured
in a locked cabinet accessible only by the study nurse.
Participants were enrolled by the study physicians, and
treatments were assigned and administered by the study nurse.
Blinding
Only the study nurse was aware of treatment assignments. All
other study personnel, including the study physicians and
laboratory personnel involved in assessing outcomes, were
blinded to the treatment assignments. Patients were not
informed of their treatment regimen.
Statistical Methods
Efﬁcacy data were evaluated using a per-protocol analysis of
patients with deﬁned treatment outcomes. Analysis was
performed using STATA version 8.0 (STATA, College Station,
Texas, United States of America) statistical software program.
Pair-wise comparisons of treatment efﬁcacy were made using
risk differences with exact 95% conﬁdence intervals. Risks of
recrudescence were estimated using the Kaplan–Meier
product limit formula with censoring for new infections.
Secondary outcomes included the presence of fever on days
1–3, parasitemia on days 2 and 3, change in hemoglobin level
between the day of enrollment and the last day of follow-up,
presence of gametocytes during any follow-up day, and the
incidence of adverse events. Other categorical variables were
compared using Chi-squared or Fisher’s exact test and
continuous variables were compared using the independent
samples t-test. The non-parametric Wilcoxon rank sum test
was used to analyze continuous data with a skewed
distribution. All reported p-values are two sided without
adjustment for multiple testing and were considered statisti-
cally signiﬁcant if ,0.05.
RESULTS
Participant Flow
Of 532 patients screened, 419 were randomized to treatment,
and 408 were enrolled in the study (Figure 1). Primary efﬁcacy
outcomes, unadjusted and adjusted by genotyping, were
available for 403 (99%) and 399 (98%) enrolled participants,
respectively.
Recruitment
The study was conducted between December 2004 and
July 2005.
Baseline Data
Among patients with efﬁcacy outcomes, there was no differ-
ence in baseline characteristics between the two treatment
groups (Table 1).
Numbers Analyzed
All 403 participants with unadjusted efﬁcacy outcomes were
included in the per-protocol analysis (Table 2).
Outcomes and Estimation
Primary efﬁcacy outcomes. The risk of recurrent sympto-
matic malaria (unadjusted, including ETF and LCF) was
signiﬁcantly lower for participants treated with artemether–
lumefantrine than for those treated with amodiaquine þ
artesunate (27% versus 42%, risk difference 15%, 95% CI
5.9%–24.2%). Similar results were seen for the risk of
recurrent parasitemia (unadjusted, including ETF, LCF, and
LPF, Table 2). The difference in risk of symptomatic malaria
and parasitemia was nearly all due to the risk of LCF (26%
artemether–lumefantrine versus 42% amodiaquine þ artesu-
nate, risk difference (16%, 95% CI 6.4%–24.7%); the risk of
ETF and LPF was similar between the treatment groups.
Genotyping revealed that nearly all episodes of recurrent
malaria were due to new infections (Table 2). In the
artemether–lumefantrine group, one participant, aged 1.2
years, experienced a convulsion on day 0 associated with
fever, following treatment with study medications, and was
classiﬁed as an ETF. The parasite density was 80,760/ll on day
0, but had decreased to 2,440/ll on day 1. A second participant
in this treatment group, aged 2.3 years, responded initially to
treatment with artemether–lumefantrine, but presented on
day 27 with fever and a parasite density of 600/ll, and after
genotyping was classiﬁed as a recrudescent LCF.
The time to recurrent malaria was signiﬁcantly shorter in
participants treated with amodiaquineþartesunate compared
to those treated with artemether–lumefantrine (Figure 2). In
patients treated with amodiaquine þ artesunate, recurrent
malaria was ﬁrst identiﬁed on day 14, with 16 of 84 new
infections identiﬁed before day 21 (n¼ 84, median 23.5 days,
range 14–28 days). In contrast, in the artemether–lumefan-
trine group only one new infection occurred before day 21 (n
¼ 52, median 25 days, range 19–28 days, p-value¼ 0.05).
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Secondary efﬁcacy outcomes. Both treatments produced
rapid clearance of parasitemia (Table 3). Although there was no
difference in parasite clearance between the two treatment
groups, patients treated with amodiaquine þ artesunate expe-
riencedmore rapidresolutionof feverondays1and2 than those
treated with artemether–lumefantrine. There was no difference
in mean change in hemoglobin between the two groups. The
proportion of patients with any gametocytes during follow-up
was signiﬁcantly lower in the artemether–lumefantrine group
(20% artemether–lumefantrine versus 31% amodiaquine þ
artesunate). Similar results were found for patients with newly
emerging gametocytes during follow-up (5% artemether–
lumefantrine versus 15% amodiaquineþ artesunate).
Ancillary Analyses
Seasonal variation. The risk of recurrent parasitemia and
recurrent symptomatic malaria in this study varied over time
(Figure 3). The risk for both outcomes was lowest between
February and March, during the dry season, and peaked from
April to June, following the rainy season. Remarkably, during
the time of peak transmission, the risk of recurrent para-
sitemia over 28 days was more than 50% and the risk of
recurrent symptomatic malaria was more than 30% for both
treatment arms.
Adverse Events
Artemether–lumefantrine and artesunate þ amodiaquine
were both well-tolerated. Overall, 261 (65%) of participants
experienced any adverse event of moderate or greater
severity, and there was no difference between the two
treatment groups (Table 3). No abnormalities in hearing or
ﬁne ﬁnger dexterity were detected. A more detailed
accounting of these results will be reported separately.
Serious adverse events occurred in two participants. One
child treated with amodiaquine þ artesunate developed
pneumonia on day 27, requiring hospitalization, but the
event was judged to be unrelated to study medications. A
second participant, treated with artemether–lumefantrine,
experienced a convulsion on day 0 (classiﬁed as an ETF as
described above), which was judged to be unlikely to be
related to the study medication.
DISCUSSION
Interpretation
In this randomized clinical trial, amodiaquine þ artesunate
and artemether–lumefantrine were both highly efﬁcacious
Figure 1. Trial Profile
AQ þ AS, amodiaquine þ artesunate; AL, artemether–lumefantrine.
DOI: 10.1371/journal.pctr.0010007.g001
.......................................................................................
Table 1. Baseline Characteristics of Patients Completing the
Study
Characteristic Treatment Group
AQ þ AS
(n ¼ 201)
AL
(n ¼ 202)
Gender (% female) 52% 51%
Median age in years (% under 5) 1.83 (92%) 2.08 (93%)
Mean (SD) temperature (8C) 37.6 (1.11) 37.5 (1.14)
Geometric mean parasite density (per ll) 22,071 20,663
Mean (SD) hemoglobin (g/dL) 10.3 (1.74) 10.3 (1.73)
Proportion with gametocytes on day 0 29% 20%
Antimalarial use in prior 2 wk 17% 19%
DOI: 10.1371/journal.pctr.0010007.t001..
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for treatment of uncomplicated malaria in Tororo, an area
with a very high level of transmission of malaria. No
recrudescences occurred in patients treated with amodia-
quine þ artesunate and only two occurred in those treated
with artemether–lumefantrine, although additional recrudes-
cences might have been detected if follow-up had been
extended to at least 42 days. The performance of artemether–
lumefantrine was consistent with results from other recent
studies from East Africa [14–16] and prior studies from Asia
[17,18], suggesting that this combination may be highly
effective in areas with considerable resistance to other
antimalarial drugs. This is welcome news for Uganda, where
artemether–lumefantrine was recently adopted as the new
ﬁrst-line therapy for uncomplicated malaria, and amodia-
quineþ artesunate has been recommended as an alternative.
In this study, despite the excellent performance of
amodiaquine þ artesunate and artemether–lumefantrine in
terms of short-term efﬁcacy, the proportion of patients
experiencing recurrent parasitemia within one month was
substantial in both treatment groups. Two-thirds of patients
treated with amodiaquine þ artesunate, and half of those
treated with artemether–lumefantrine, were parasitemic
during 28 days of follow-up. Nearly all recurrent parasitemias
were characterized as new infections. Nonetheless, even with
the more efﬁcacious regimen (artemether–lumefantrine),
over a quarter of patients had recurrent illness, demonstrat-
ing the importance of reinfection in areas of very high
malaria transmission. This result highlights the need to re-
evaluate the approach to treatment of recurrent episodes of
malaria following initial ACT therapy. In our study, partic-
ipants received quinine as second-line treatment. However it
is unclear whether quinine, the same ACT, or a different ACT
would be the optimal treatment. Given that nearly all
recurrent parasitemias were due to new infections, it may
be reasonable to retreat with the same ACT regimen, rather
than with quinine. Our results also indicate that integration
of approaches to control malaria is essential. In an area of
South Africa with lower-intensity transmission, the combina-
tion of vector control measures and provision of artemether–
lumefantrine dramatically decreased the malaria burden [19].
In areas of high transmission, even highly efﬁcacious
antimalarial treatments may need to be given repeatedly,
which has obvious cost implications, and may signiﬁcantly
impact on the safety of drug regimens.
We found that artemether–lumefantrine was superior to
amodiaquine þ artesunate for preventing new infections,
consistent with recent results from Zanzibar [15]. Because
both artemisinin derivatives are rapidly eliminated, our
results suggest that lumefantrine has a greater post-treatment
prophylactic effect than amodiaquine, perhaps due to the
waning of amodiaquine efﬁcacy due to drug resistance [20].
Delayed drug clearance may prevent new infection with drug
sensitive parasites, but is likely to contribute to the selection
of drug resistance, and may impact on long-term efﬁcacy [21].
In Zanzibar, artemether–lumefantrine was associated with
post-treatment selection of the pfmdr1 86N allele, which may
play a role in lumefantrine resistance [15,22]. As ACT use
becomes widespread in areas with high levels of malaria
transmission, it will be important to monitor closely for the
selection of parasites that are resistant to artemisinin partner
drugs. The beneﬁts of a regimen that prevents recurrent
infection, particularly in areas of high transmission, could be
substantial. However, these beneﬁts will need to be weighed
against the potential for driving drug resistance.
Generalizability
The risk of recurrent parasitemia and symptomatic malaria
had signiﬁcant seasonal variation. Although malaria trans-
mission occurs year-round in Tororo, the difference in
transmission between dry and wet seasons had a substantial
impact on risk of new infection, and therefore on the need
.......................................................................................................................................................................................
Table 2. Primary Treatment Outcomes
Outcome AQ þ AS (n ¼ 201) AL (n ¼ 202) RD (95% CI) p-Value
Unadjusted resultsa Recurrent symptomatic malariab 42% 27% 15% (5.9% to 24.2%) 0.001
Recurrent parasitemiac 66% 51% 16% (6.2% to 25.2%) 0.001
WHO outcome, number (%) ETF 0 1 (1%) 0.5% (1.5% to 0.5%) 1.0
LCF 84 (42%) 53 (26%) 16% (6.4% to 24.7%) 0.001
LPF 49 (24%) 48 (24%) 0.6% (7.7% to 9.0%) 0.89
ACPR 68 (34%) 100 (50%) 16% (25.2% to 6.2%) 0.001
Adjusted resultsa Recurrent symptomatic malariab Due to recrudescence 0 2 (1%) 1.0% (2.4% to 0.4%) 0.50
Recurrent parasitemiac Due to recrudescence 0 2 (1%) 1.0% (2.4% to 0.4%) 0.50
aResults unadjusted or adjusted by genotyping.
bETF or LCF.
cETF, LCF, or LPF.
DOI: 10.1371/journal.pctr.0010007.t002..
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Figure 2. Day of Recurrent Malaria due to New Infection Stratified by
Treatment Group
DOI: 10.1371/journal.pctr.0010007.g002
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for retreatment. The seasonal variation is important to
recognize when comparing results of drug efﬁcacy studies
conducted at the same site. More broadly, these results
highlight the importance of the level of transmission in
determining risks of recurrent malaria after therapy. In a
prior drug efﬁcacy study conducted at the same site between
September 2003 and March 2004, the unadjusted risk of
recurrent infection at 28 days was 74% for amodiaquine þ
artesunate versus 59% for amodiaquine þ sulfadoxine-
pyrimethamine, with 12% versus 18% risk of recrudescence,
respectively [10]. For amodiaquine þ artesunate, the differ-
ence between the past results and those reported here is likely
due to seasonal and/or annual variation (impacting on risk of
recurrent parasitemia), as well as slight differences in
genotyping techniques (impacting on risk of recrudescence).
In the prior study, genotyping was performed by analyzing for
polymorphisms in MSP-2 only. In this study, the genotyping
technique was reﬁned by analyzing all samples initially
identiﬁed as recrudescent by MSP-2 analysis for polymor-
phisms in MSP-1. Using this reﬁned technique, the majority
of samples initially classiﬁed as recrudescent were reclassiﬁed
as new infections. Amodiaquine þ sulfadoxine-pyrimeth-
amine was not included in this study and thus cannot be
directly compared to artemether–lumefantrine. However, the
risks of recurrent parasitemia for amodiaquine þ artesunate
versus amodiaquine þ sulfadoxine–pyrimethamine in the
prior study (74% versus 59%, risk difference 15%, 95% CI
5%–25%) were similar to those for amodiaquineþ artesunate
versus artemether–lumefantrine in the current study (66%
versus 51%, risk difference 16%, 95% CI 6%–25%).
Overall Evidence
A systematic review of the six-dose regimen of artemether–
lumefantrine published in 2005 identiﬁed nine randomized
controlled trials, including four studies conducted in Africa
(in Burundi, The Gambia, Tanzania, and Uganda) [14,16,23–
25]. The reviewers concluded that the six-dose regimen of
artemether–lumefantrine appeared to be more effective than
regimens that did not contain an artemisinin. In the two
studies which compared artemether–lumefantrine to amo-
diaquineþ artesunate (an effectiveness study in Tanzania and
an efﬁcacy trial in Burundi), artemether–lumefantrine
resulted in fewer failures by day 28 in Tanzania, and fewer
parasitological failures by day 14 in both Tanzania and
Burundi [16,24]. The study from Uganda compared super-
vised versus unsupervised administration of artemether–
lumefantrine and found that both methods were highly
effective (98% genotyping-adjusted cure at day 28 with both
methods) [14]. A more recent study comparing artemether–
lumefantrine to amodiaquineþ artesunate in Zanzibar found
that both regimens were highly efﬁcacious after 42-d follow-
up (genotyping-adjusted cure rates 94% and 91%, respec-
tively, when uncertain PCR results were deﬁned as re-
.......................................................................................................................................................................................
Table 3. Secondary Outcomes
Outcome Treatment Group p-Value
AQ þ AS (n ¼ 201) AL (n ¼ 202)
Parasite clearance Parasitemia on day 2, number (%) 5 (2.5%) 4 (2.0%) 0.75
Parasitemia on day 3, number (%) 1 (0.5%) 1 (0.5%) 1.0
Fever clearance Temperature . 37.5 8C on day 0, number (%) 85 (42%) 86 (43%) 1.0
Temperature . 37.5 8C on day 1, number (%) 4 (2.0%) 18 (8.9%) 0.003
Temperature . 37.5 8C on day 2, number (%) 0 7 (3.4%) 0.01
Temperature . 37.5 8C on day 3, number (%) 2 (1.0%) 7 (3.4%) 0.17
Mean increase (SD) in hemoglobin (g/dL) 1.35 (1.71) 1.39 (1.76) 0.79
Gametocytes during follow-up 31% 20% 0.01
Newly emerging gametocytes during follow-upa 15% 5% 0.004
Adverse events Adverse event of at least moderate severity 136 (68%) 125 (62%) 0.25
Serious adverse event 1 (0.5%) 1 (0.5%) 1.0
aIncludes only those patients with no gametocytes present on day 0.
DOI: 10.1371/journal.pctr.0010007.t003..
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Figure 3. Risk of Recurrent Parasitemia and Recurrent Malaria Stratified
by Date of Enrollment
The peak in risks corresponds to the period following the rainy season. The p-
values are for differences in risks across the different time periods for each
regimen.
DOI: 10.1371/journal.pctr.0010007.g003
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........................................................................................
infections, p ¼ 0.115), and that artemether–lumefantrine
provided greater protection against re-infection compared
with amodiaquine þ artesunate [15].
Our study adds to the evidence base on the comparative
efﬁcacy of ACTs in Africa. The results from Tororo support
the ﬁndings of the Zanzibar trial, although the overall risk of
recurrent malaria at 28 days was substantially higher in our
study (66% amodiaquine þ artesunate versus 51% arte-
mether–lumefantrine) than in Zanzibar (28% amodiaquineþ
artesunate versus 7% artemether–lumefantrine, likely reﬂect-
ing the greater level of malaria transmission at our study site
[15]. We found that amodiaquine þ artesunate and arte-
mether–lumefantrine were both highly efﬁcacious, but each
regimen has limitations. The lifespan of amodiaquine þ
artesunate may be limited by resistance to amodiaquine, and
the current lack of co-formulation of this regimen may
reduce adherence, although a co-formulated combination
may be available soon. Both regimens are much more
expensive than older antimalarial drugs, and their wide-
spread use in Africa has been challenged by limited
availability. For both ACT regimens, the high rate of re-
infection and the implications of frequent retreatment is a
major concern. Artemisinin combination therapy offers an
important step forward for the treatment of malaria in
Africa, but continued research into effective, safe, and
affordable antimalarial regimens, consideration of the com-
parative post-treatment effects of different therapies, and
integration of treatment with preventive methods, will be
necessary to establish effective and sustainable malaria
control policies.
SUPPORTING INFORMATION
CONSORT Checklist
Found at 10.1371/journal.pctr.0010007.sd001 (51 KB DOC).
Trial Protocol
Found at 10.1371/journal.pctr.0010007.sd002 (821 KB DOC).
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